Cancer Prevention Agent Development Program 2012-2017

The Cancer Prevention Agent Development Program 2012-2017 is a National Cancer Institute (NCI) indefinite delivery/indefinite quantity (IDIQ) contract vehicle designed to support early-phase clinical research focused on cancer prevention agents. The primary objective of this contract vehicle is to provide critical infrastructure and laboratory support for designing and conducting Phase I and Phase II clinical trials that explore potential cancer preventive agents across various molecular classes. By characterizing the biological effects of new preventive agents and developing insights into cancer prevention mechanisms, the program aims to advance scientific understanding of potential cancer prevention strategies.

The task orders under this IDIQ consistently involve research institutions like Northwestern University, University of Arizona, University of Wisconsin, and University of Texas MD Anderson Cancer Center, each receiving delivery orders ranging from approximately $100,000 to $4.2 million. The contracts are predominantly cost-no-fee and do not utilize small business set-aside designations. Typical task orders involve clinical trials examining interventions such as vaccines, drugs, and nutritional compounds for potential cancer prevention, with performance periods commonly spanning 2-4 years. The research spans multiple cancer types, including breast, prostate, lung, and colorectal cancers, and often involves randomized controlled trials, biomarker studies, and immunogenicity assessments. All task orders are issued by the National Cancer Institute and focus on early-phase clinical research to develop novel cancer prevention approaches.